<DOC>
	<DOCNO>NCT02963064</DOCNO>
	<brief_summary>This single-arm , open label , Phase 1 study ass safety tolerability CD34+CD90+ hematopoietic stem cell ( HSC ) allograft infuse patient SCID condition transplantation AMG 191 , antibody target CD117 present endogenous HSC . The target dose CD34+CD90+ HSC &gt; 1 x 10^6 cells/kg optimal conditioning dose AMG 191 determine dose escalation .</brief_summary>
	<brief_title>AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study SCID Patients</brief_title>
	<detailed_description>Hematopoietic stem cell transplantation ( HCT ) proven cure severe combine immunodeficiency ( SCID ) , rare disorder patient functional lymphocyte . Unless treat , patient SCID generally die infection age two . The success HCT depend type donor , often feasible find fully human leukocyte antigen ( HLA ) -matched unrelated donor due need transplant early life infection develop . As result , family member partially HLA-matched ( haploidentical ) often donate blood stem cell transplant . There three primary risk associate poor HCT outcome SCID patient : 1 ) chemotherapeutic drug sometimes give prepare patient HCT improve chance successful engraftment ; treatment ( call `` conditioning '' ) deleterious short long-term side effect SCID patient especially vulnerable ; 2 ) risk develop graft-versus-host disease ( GVHD ) due reaction donor T cell contain allografts recipient tissue cause serious , life-threatening complication , especially donor partially HLA-matched ; 3 ) conditioning use true stem cell may engraft , prevents development long-term functioning immune system , especially B lymphocytes . As consequence many patient need life-long gammaglobulin replacement therapy . This study investigate combine , two-step approach expect improve outcome HCT SCID : It phase 1 study . Hence , study test safety two step approach . The first part study test experimental conditioning treatment expect less toxic patient standard chemotherapy . This treatment involve give one time intravenous dose protein , call monoclonal antibody , bind specific molecule surface cell , call c-kit CD117 . The antibody use call AMG 191 . AMG 191 expect result depletion recipient bone marrow stem cell thereby improve donor blood stem cell engraftment recipient 's bone marrow development immune system donor . Patients follow clearance antibody blood pharmacokinetic ( PK ) study . The second part test SCID patient condition transplant AMG 191 good T-cells remove donor graft . T-cells normally act attack foreign pathogens virus . However , transplant recipient part blood stem cell graft , T-cells cause harm mistakenly attack normal tissue , include lymphoid organ recipient , result GVHD subtle form GVHD call subclinical GVHD deleterious immune function . While removal T-cells blood stem cell graft novel , graft study stringent T-cell removal patient SCID particularly prone develop GVHD . Grafts first undergo standard selection CD34+ cell reduce donor T-cells enrich blood stem cell . A second enrichment step purify blood stem cell away remain T-cells stain CD34-selected cell another CD34 binding antibody plus antibody bind CD90 . CD34+CD90+ cell , represent purify stem cell fraction , isolate use cell sorter . This part study determine GVHD reduce equivalent improve immune function achieve compare standard graft .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key All patient group must : 1 . Primary Immune Deficiency define specific criterion , include limited follow subtypes : 1 . T , B+ , NK : IL2Rcγ deficient , JAK3deficient 2 . T , B , NK+ : RAG1/2 deficient , Artemisdeficient 3 . T , B+ , NK+ : IL7Rα deficient , CD3 subunit deficient , CD45 deficient 2 . Acceptable organ function define study protocol 3 . Life expectancy least 8 week 4 . Female patient childbearing potential willing use effective contraceptive method duration study participation Key Inclusion Criteria patient &gt; /= two year age prior allogeneic bone marrow transplant ( BMT ) : 1 . Prior donor appropriate age ( ≥ 5 year old ) available recollection stem cell apheresis 2 . Previous allogeneic BMT ( &gt; 2 year prior ) poor graft function define one following : 1 . Inadequate B cell engraftment , 2 . Incomplete T cell reconstitution , 3 . Severe clinical symptom explain poor immunity Key Inclusion criterion specific patient newly diagnose SCID : 1 . Haploidentical donor appropriate age ( &gt; 5 year old ) HLAmatched unrelated donor available apheresis 1 . Patients acute uncontrolled infection 2 . Patients receive investigational agent , concurrent biological , chemotherapy , radiation therapy 3 . Patients active malignancy 4 . Pregnant woman 5 . Women nurse wish discontinue breast feeding 6 . Lansky/Karnofsky performance score &lt; 50 % 7 . Patients certain defined SCID subtypes , include : 1 . Omenn syndrome 2 . Leaky SCID 3 . Reticular dysgenesis 4 . Adenosine deaminase deficiency 5 . Purine nucleoside phosphorylase deficiency 8 . For patient prior HCT , evidence donor myeloid chimerism peripheral blood STR analysis . 9 . For patient newly diagnose SCID , HLAmatched sibling eligible donate hematopoietic cell 10 . Active GVHD within 6 month prior enrollment , immunosuppressive therapy GVHD .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Immunodeficiency</keyword>
	<keyword>Pediatric</keyword>
	<keyword>SCID</keyword>
	<keyword>Bone Marrow Transplantation</keyword>
	<keyword>GVHD</keyword>
	<keyword>Stem Cells</keyword>
	<keyword>Chimerism</keyword>
	<keyword>Transplant</keyword>
	<keyword>BMT</keyword>
</DOC>